UK company Atlas Genetics Ltd. was founded in 2005 as a spin-out from Osmetech PLC and the University of Bath to exploit the point of care (POC) market for infectious diseases. When John Clarkson, PhD, joined US-based and UK-listed Osmetech as incoming CEO of the unit that became Atlas Genetics Ltd. he recognized that the company was under-utilizing some of its IP assets and saw both the opportunity – and the challenges – of developing its infectious disease diagnostic chemistry.
Clarkson had to strike the right balance of investment: it had to remain modest until the company had developed a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?